Entering text into the input field will update the search result below

NLSP NLS Pharmaceutics AG
Stock Price & Overview

$0.80-0.04 (-4.76%)3:59 PM 09/21/23
NASDAQ | $USD | Post-Market: $0.78 -0.02 (-2.50%) 4:40 PM


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

Ratings Summary

Now6M ago
SA Analysts
Not CoveredRating: Not Covered
Wall Street
Not CoveredRating: Not Covered
Not CoveredRating: Not Covered

Ratings Summary

SA Analysts
Wall Street
Now3M ago6M ago
-Rating: Not Covered
-Rating: Not Covered
-Rating: Not Covered
-Rating: Not Covered
-Rating: Not Covered

See NLSP ratings with Premium.

Company Profile

NLS Pharmaceutics AG logo
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
  • The Circle 6
  • Zurich, 8058
  • Switzerland
Phone Number
41 44 512 21 50
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.